Literature DB >> 2787872

Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response.

A C van der Wal1, P K Das, D Bentz van de Berg, C M van der Loos, A E Becker.   

Abstract

The immunophenotypical features of the cellular infiltrates in different types of human atherosclerotic lesions, including diffuse intimal thickening as a potential but controversial precursor lesion, have been examined using monoclonal antibodies. Special emphasis is put on monocytes/macrophages, lymphocytes, and their possible interactions. Immuno-double staining techniques have been employed to study these aspects. T lymphocytes and macrophages were detected in diffuse intimal thickening, fatty streaks, and atheromatous plaques. In some lesions a predominance of suppressor/cytotoxic lymphocytes was found, whereas in other lesions mixtures of T suppressor/cytotoxic cells and T helper/inducer cells were found in ratios varying from 1:1 to 4:1. A substantial number of T cells and macrophages was considered to be immunoactivated because of the expression of HLA-DR and, to a lesser extent, of I12 receptor molecules. The activation was particularly evident at sites of close cell-to-cell contact between monocytes/macrophages and lymphocytes. These observations suggest that a specific in situ immune mediated hypersensitivity reaction is associated with the development of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787872

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  56 in total

1.  The effect of short-term, high glucose concentration on endothelial cells and leukocytes in a 3D in vitro human vascular tissue model.

Authors:  H Gappa-Fahlenkamp; A S Shukla
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-01-28       Impact factor: 2.416

2.  Galectin-3 expression in human atherosclerotic lesions.

Authors:  M Nachtigal; Z Al-Assaad; E P Mayer; K Kim; M Monsigny
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 3.  Immunology of atherosclerosis: the promise of mouse models.

Authors:  A H Lichtman; M Cybulsky; F W Luscinskas
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

Review 4.  Lymphocytes and the adventitial immune response in atherosclerosis.

Authors:  Kirsti A Campbell; Michael J Lipinski; Amanda C Doran; Marcus D Skaflen; Valentin Fuster; Coleen A McNamara
Journal:  Circ Res       Date:  2012-03-16       Impact factor: 17.367

Review 5.  Adaptive immunity in atherogenesis: new insights and therapeutic approaches.

Authors:  Andrew H Lichtman; Christoph J Binder; Sotirios Tsimikas; Joseph L Witztum
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

6.  Food restriction and fish oil suppress atherogenic risk factors in lupus-prone (NZB x NZW) F1 mice.

Authors:  Alagarraju Muthukumar; Khaliquz Zaman; Richard Lawrence; Jeffery L Barnes; Gabriel Fernandes
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

7.  Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima. Role of cell-mediated immunity in human atherogenesis.

Authors:  H Kishikawa; T Shimokama; T Watanabe
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Balloon catheter de-endothelialization of the nude rat carotid. Response to injury in the absence of functional T lymphocytes.

Authors:  G A Ferns; M A Reidy; R Ross
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

Review 9.  Inflammation and immune system interactions in atherosclerosis.

Authors:  Bart Legein; Lieve Temmerman; Erik A L Biessen; Esther Lutgens
Journal:  Cell Mol Life Sci       Date:  2013-02-21       Impact factor: 9.261

10.  Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial.

Authors:  Victor Y Cheng; Piotr J Slomka; Marie Ahlen; Louise E J Thomson; Alan D Waxman; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2009-12-15       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.